Literature DB >> 8985041

Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks.

M H Gaber1, N Z Wu, K Hong, S K Huang, M W Dewhirst, D Papahadjopoulos.   

Abstract

PURPOSE: The purpose of this study was to determine whether hyperthermic exposure would accelerate drug release from thermosensitive sterically stabilized liposomes and enhance their extravasation in tumor tissues.
MATERIALS AND METHODS: In vivo fluorescence video microscopy was used to measure the extravasation of liposomes, as well as release of their contents, in a rat skin flap window chamber containing a vascularized mammary adenocarcinoma under defined thermal conditions (34 degrees, 42 degrees, and 45 degrees C). Images of tissue areas containing multiple blood vessels were recorded via a SIT camera immediately before, and for up to 2 h after i.v. injection of two liposome populations with identical lipid composition: one liposome preparation was surface labeled with Rhodamine-PE (Rh-PE) and the other contained either Doxorubicin (Dox) or calcein at self-quenching concentrations. The light intensity of the entire tissue area was measured at 34 degrees C (the physiological temperature of the skin) for 1 h, and at 42 degrees or 45 degrees C for a second hour. These measurements were then used to calculate the fluorescent light intensity arising from each tracer (liposome surface label and the released contents) inside the vessel and in the interstitial region.
RESULTS: The calculated intensity of Rh-PE for the thermosensitive liposomes in the interstitial space (which represents the amount of extravasated liposomes) was low during the first hour, while temperature was maintained at 34 degrees C and increased to 47 times its level before heating, when the tumor was heated at 42 degrees or 45 degrees C for 1 h. The calculated intensity of the liposome contents (Dox) in the interstitial space was negligible at 34 degrees C, and increased by 38- and 76-fold, when the tumor was heated at 42 degrees and 45 degrees C for 1 h, respectively. Similar values were obtained when calcein was encapsulated in liposomes instead of Dox. A similar increase in liposome extravasation was seen with nonthermosensitive liposomes, but negligible release of Dox occurred when the window chamber was heated to 45 degrees C for 1 h. Extravasation of liposomes continued after heating was stopped, but content release stopped after removal of heat. Release of Dox from extravasated liposomes was also seen if heating was applied 24 h after liposome administration, but no further enhancement of liposome extravasation occurred in this case.
CONCLUSIONS: Our data suggest that hyperthermia can be used to selectively enhance both the delivery and the rate of release of drugs from thermosensitive liposomes to targeted tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8985041     DOI: 10.1016/s0360-3016(96)00389-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  51 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer.

Authors:  Zeljko Vujaskovic; Dong W Kim; Ellen Jones; Lan Lan; Linda McCall; Mark W Dewhirst; Oana Craciunescu; Paul Stauffer; Vlayka Liotcheva; Allison Betof; Kimberly Blackwell
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

3.  Localized delivery of doxorubicin in vivo from polymer-modified thermosensitive liposomes with MR-guided focused ultrasound-mediated heating.

Authors:  Terence Ta; Elizabeth Bartolak-Suki; Eun-Joo Park; Kavon Karrobi; Nathan J McDannold; Tyrone M Porter
Journal:  J Control Release       Date:  2014-08-23       Impact factor: 9.776

4.  Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells.

Authors:  Antonella Accardo; Silvia Mannucci; Elena Nicolato; Federica Vurro; Carlo Diaferia; Pietro Bontempi; Pasquina Marzola; Giancarlo Morelli
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

Review 5.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

6.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

Review 7.  A physiological perspective on the use of imaging to assess the in vivo delivery of therapeutics.

Authors:  Shengping Qin; Brett Z Fite; M Karen J Gagnon; Jai W Seo; Fitz-Roy Curry; Frits Thorsen; Katherine W Ferrara
Journal:  Ann Biomed Eng       Date:  2013-09-10       Impact factor: 3.934

8.  Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.

Authors:  Sergio Dromi; Victor Frenkel; Alfred Luk; Bryan Traughber; Mary Angstadt; Monica Bur; Jason Poff; Jianwu Xie; Steven K Libutti; King C P Li; Bradford J Wood
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

Review 9.  Thermosensitive liposomes for localized delivery and triggered release of chemotherapy.

Authors:  Terence Ta; Tyrone M Porter
Journal:  J Control Release       Date:  2013-04-11       Impact factor: 9.776

10.  Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment.

Authors:  Oliver K Appelbe; Qingbei Zhang; Charles A Pelizzari; Ralph R Weichselbaum; Stephen J Kron
Journal:  Mol Pharm       Date:  2016-09-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.